Literature DB >> 9573255

High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments.

K E Pollok1, H Hanenberg, T W Noblitt, W L Schroeder, I Kato, D Emanuel, D A Williams.   

Abstract

Primary human T lymphocytes are powerful targets for genetic modification, although the use of these targets in human gene therapy protocols has been hampered by low levels of transduction. We have shown previously that significant increases in the transduction of hematopoietic stem and progenitor cells with retroviral vectors can be obtained by the colocalization of the retrovirus and target cells on specific fibronectin (FN) adhesion domains (H. Hanenberg, X. L. Xiao, D. Dilloo, K. Hashino, I. Kato, and D. A. Williams, Nat. Med. 2:876-882, 1996). We studied the transfer of genes into primary T lymphocytes by using FN-assisted retroviral gene transfer. Activated T lymphocytes were infected for three consecutive days on the recombinant FN fragment CH-296 with a retroviral vector encoding the murine B7-1 protein. Transduced lymphocytes were analyzed for murine B7-1 expression, and it was found that under optimal conditions, 80 to 89% of the CD3+ lymphocytes were transduced. Gene transfer was predominantly augmented by the interaction between VLA-4 on the T lymphocytes and the FN adhesion site CS-1. Adenosine deaminase (ADA)-deficient primary T lymphocytes transduced on CH-296 with a retrovirus encoding murine ADA (mADA) exhibited levels of mADA activity severalfold higher than the levels of the endogenous human ADA protein observed in normal human T lymphocytes. Strikingly, the long-term expression of the transgene was dependent on the activation status of the lymphocytes. This approach will have important applications in human gene therapy protocols targeting primary T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9573255      PMCID: PMC110042          DOI: 10.1128/JVI.72.6.4882-4892.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  T-cell gene therapy.

Authors:  K M Hege; M R Roberts
Journal:  Curr Opin Biotechnol       Date:  1996-12       Impact factor: 9.740

2.  High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes.

Authors:  B A Bunnell; L M Muul; R E Donahue; R M Blaese; R A Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 3.  Adenosine deaminase deficiency: molecular basis and recent developments.

Authors:  R Hirschhorn
Journal:  Clin Immunol Immunopathol       Date:  1995-09

4.  Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency.

Authors:  D B Kohn; K I Weinberg; J A Nolta; L N Heiss; C Lenarsky; G M Crooks; M E Hanley; G Annett; J S Brooks; A el-Khoureiy
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

5.  PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.

Authors:  M S Hershfield
Journal:  Clin Immunol Immunopathol       Date:  1995-09

6.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

7.  Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter.

Authors:  J S Harms; G A Splitter
Journal:  Hum Gene Ther       Date:  1995-10       Impact factor: 5.695

8.  Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation.

Authors:  C E Dunbar; M Cottler-Fox; J A O'Shaughnessy; S Doren; C Carter; R Berenson; S Brown; R C Moen; J Greenblatt; F M Stewart
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

Review 9.  Transfer of genes to humans: early lessons and obstacles to success.

Authors:  R G Crystal
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

10.  Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.

Authors:  C Bordignon; L D Notarangelo; N Nobili; G Ferrari; G Casorati; P Panina; E Mazzolari; D Maggioni; C Rossi; P Servida; A G Ugazio; F Mavilio
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

View more
  26 in total

1.  Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.

Authors:  Pritha Agarwalla; Edikan A Ogunnaike; Sarah Ahn; Frances S Ligler; Gianpietro Dotti; Yevgeny Brudno
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

2.  In vivo selection of CD4(+) T cells transduced with a gamma-retroviral vector expressing a single-chain intrabody targeting HIV-1 tat.

Authors:  Stephen E Braun; Ran Taube; Quan Zhu; Fay Eng Wong; Akikazu Murakami; Erick Kamau; Markryan Dwyer; Gang Qiu; Janet Daigle; Angela Carville; R Paul Johnson; Wayne A Marasco
Journal:  Hum Gene Ther       Date:  2012-09       Impact factor: 5.695

3.  Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of engrafting human hematopoietic stem cells.

Authors:  Dustin J Maxwell; Jesper Bonde; David A Hess; Sarah A Hohm; Ryan Lahey; Ping Zhou; Michael H Creer; David Piwnica-Worms; Jan A Nolta
Journal:  Stem Cells       Date:  2007-11-29       Impact factor: 6.277

4.  Efficient Transduction of Human and Rhesus Macaque Primary T Cells by a Modified Human Immunodeficiency Virus Type 1-Based Lentiviral Vector.

Authors:  Huan He; Jing Xue; Weiming Wang; Lihong Liu; Chaobaihui Ye; Zhe Cong; Jason T Kimata; Chuan Qin; Paul Zhou
Journal:  Hum Gene Ther       Date:  2016-12-29       Impact factor: 5.695

5.  Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.

Authors:  K Liu; S A Rosenberg
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

6.  Expression of herpes simplex virus ICP47 and human cytomegalovirus US11 prevents recognition of transgene products by CD8(+) cytotoxic T lymphocytes.

Authors:  C Berger; S Xuereb; D C Johnson; K S Watanabe; H P Kiem; P D Greenberg; S R Riddell
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Towards antigen-specific Tregs for type 1 diabetes: Construction and functional assessment of pancreatic endocrine marker, HPi2-based chimeric antigen receptor.

Authors:  Ilian A Radichev; Jeongheon Yoon; David W Scott; Kurt Griffin; Alexei Y Savinov
Journal:  Cell Immunol       Date:  2020-09-30       Impact factor: 4.868

8.  Retrovirus-associated heparan sulfate mediates immobilization and gene transfer on recombinant fibronectin.

Authors:  Pedro Lei; Bharat Bajaj; Stelios T Andreadis
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Telomere loss, senescence, and genetic instability in CD4+ T lymphocytes overexpressing hTERT.

Authors:  Alexander Röth; Gabriela M Baerlocher; Mike Schertzer; Elizabeth Chavez; Ulrich Dührsen; Peter M Lansdorp
Journal:  Blood       Date:  2005-03-01       Impact factor: 22.113

10.  Peptide nanofibrils boost retroviral gene transfer and provide a rapid means for concentrating viruses.

Authors:  Maral Yolamanova; Christoph Meier; Alexey K Shaytan; Virag Vas; Carlos W Bertoncini; Franziska Arnold; Onofrio Zirafi; Shariq M Usmani; Janis A Müller; Daniel Sauter; Christine Goffinet; David Palesch; Paul Walther; Nadia R Roan; Hartmut Geiger; Oleg Lunov; Thomas Simmet; Jens Bohne; Hubert Schrezenmeier; Klaus Schwarz; Ludger Ständker; Wolf-Georg Forssmann; Xavier Salvatella; Pavel G Khalatur; Alexei R Khokhlov; Tuomas P J Knowles; Tanja Weil; Frank Kirchhoff; Jan Münch
Journal:  Nat Nanotechnol       Date:  2013-01-20       Impact factor: 39.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.